2024 EADV congress: Galderma presents long-term efficacy and safety of nemolizumab for atopic dermatitis and prurigo nodularis.

Galderma will share new findings from the ARCADIA and OLYMPIA clinical trials at the 2024 EADV congress in Amsterdam. The data will highlight the long-term efficacy and safety of nemolizumab for treating moderate-to-severe atopic dermatitis and prurigo nodularis. Results indicate sustained improvements in skin lesions, itch, and quality of life, with a consistent safety profile. Nemolizumab targets IL-31 cytokine signaling, addressing key symptoms of these conditions.